This week�� palette of dividend stocks increasing payouts (and thereby upping their dividend yields) spans a broad set of industries across just a few stocks. Of course, if you��e an investor primarily concerned with income generation, this week�� list of dividend stocks increasing payouts will appeal to you anyway, regardless of business. (All yields as of June 6.)
Best Construction Stocks To Own Right Now: Synergy Pharmaceuticals Inc (SGYP)
Synergy Pharmaceuticals, Inc., incorporated on February 11, 1992, is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Company�� lead product candidate is plecanatide, a guanylyl cyclase C (GC-C), receptor agonist, to treat GI disorders, primarily chronic constipation (CC), and constipation-predominant-irritable bowel syndrome (IBS-C). It is also developing SP-333, the second generation GC-C receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis (UC). The Company�� active pharmaceutical ingredients (APIs) and the final formulated drug products are manufactured for it by third party contractors.
As of December 31, 2011, the Company was developing plecanatide, a synthetic hexadecapeptide designed to mimic the actions of the GI hormone uroguanylin, for the treatment of CC and IBS-C. Plecanatide is an agonist of GC-C receptor. As of December 31, 2011, the Company was dosing patients in an 800-patient Phase II/III clinical trial of plecanatide to treat. It is also developing a second generation GC-C receptor analog, SP-333, which is in pre-clinical development for the treatment of gastrointestinal inflammatory diseases. SP-333 is a synthetic analog of uroguanylin, a natriuretic hormone.
The Company competes with Ironwood Pharmaceuticals, Inc., Forest Laboratories, Inc., Takeda Pharmaceuticals America, Inc., Sucampo Pharmaceuticals, Inc., Salix Pharmaceuticals, Inc. and Shire Plc.
Advisors' Opinion:- [By Monica Gerson]
Breaking news
Time Warner Cable (NYSE: TWC) reported a drop in its third-quarter profit. Time Warner Cable's quarterly profit fell to $532 million, or $1.84 per share, from $808 million, or $2.60 per share, in the year-ago period. To read the full news, click here. Synergy Pharmaceuticals (NASDAQ: SGYP) today announced the start of a phase 2 clinical trial to evaluate the safety and efficacy of SP-333, its second-generation GC-C agonist and once-daily oral treatment, in adult patients with opioid-induced constipation (OIC). To read the full news, click here. Cigna (NYSE: CI) reported a 19% rise in its third-quarter earnings and lifted its full-year earnings outlook. To read the full news, click here. Charm Communications (NASDAQ: CHRM) announced today that the special committee of the Company's board of directors, consisting of independent directors Mr. Zhan Wang, Mr. Andrew J. Rickards and Mr. Gang Chen, has retained China Renaissance Securities (Hong Kong) Limited as its financial advisor and Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP as its legal advisor. To read the full news, click here.Posted-In: Bank of America US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets
- [By Sean Williams]
Finally, Synergy Pharmaceuticals (NASDAQ: SGYP ) may have had the wildest week of them all. Synergy's share price spiked 16% on Tuesday as an analyst at Cantor Fitzgerald raised her peak sales estimate for plecanatide, the company's midstage drug for chronic idiopathic constipation and irritable bowel syndrome with constipation, to $1.58 billion from $1.05 billion, as clinical data has been stronger than expected. However, the company didn't return the favor to shareholders by -- the very next day, mind you ��announcing a secondary offering of 16.375 million shares. The downside of clinical-stage companies is the always apparent risk of dilution. Shares have lost 25% since their Tuesday close.
Top 10 Railroad Stocks To Own For 2014: ProShares Short MSCI Emerging Markets (EUM)
ProShares Short MSCI Emerging Markets (the Fund) seeks daily investment results that correspond to the inverse (opposite) of the daily performance of the MSCI Emerging Markets Index. The MSCI Emerging Markets Index adjusts the market capitalization of index constituents for free float and targets for index inclusion 85% of free float-adjusted market capitalization in each industry group in global emerging markets countries. The Fund takes positions in securities and/or financial instruments that, in combination, should have similar daily return characteristics as -100% of the daily return of the MSCI Emerging Markets Index. The MSCI Emerging Markets Index is a price return index. The Fund�� investment advisor is ProShare Advisors LLC. Advisors' Opinion:- [By Anthony Mirhaydari]
Editor�� note: This column is part of our Best Stocks for 2014 contest. Anthony Mirhaydari’s pick for the contest is the�ProShares Short MSCI Emerging Markets ETF�(EUM).
Top 10 Railroad Stocks To Own For 2014: Publicis Groupe SA (PUB)
Publicis Groupe SA (Publicis Groupe) is a France-based company engaged in the provision of advertising services, specialized agencies and marketing services (SAMS) and media services. Its primary activities include communications, media agency, and digital and healthcare communications. Publicis Groupe offers local and international clients a complete range of advertising services through three global advertising networks: Leo Burnett, Publicis, Saatchi & Saatchi, and two multi-hub networks, Fallon and 49%-owned Bartle Bogle Hegarty. In August 2013, the Company acquired Engauge Marketing LLC. In November 2013, it announced the acquisition of ETO. In November 2013, it acquired majority of shares of Walker Media from M&C Saatchi PLC. In December 2013, Publicis Groupe SA acquired Synergize Digital Pty Ltd. In December 2013, it acquired Verilogue Inc. In January 2014, it acquired Qorvis Communications. Advisors' Opinion:- [By Jonathan Morgan]
European stocks climbed to a six-week high as Publicis (PUB) Groupe SA posted increased profit, London Stock Exchange Group Plc reported higher revenue and fewer Americans than forecast filed jobless-benefit claims.
Top 10 Railroad Stocks To Own For 2014: Fifth Street Finance Corp (FSC)
Fifth Street Finance Corp. is a specialty finance company that lends to and invests in small and mid-sized companies in connection with investments by private equity sponsors. The Company�� investment objective is to maximize its portfolio's total return by generating current income from its debt investments and capital appreciation from its equity investments. As of September 30, 2011, 90.9% of its portfolio consisted of debt investments that were secured by first or second priority liens on the assets of its portfolio companies. As of September 30, 2011, it held equity investments consisting of common stock, preferred stock or other equity interests in 27 out of 65 portfolio companies. It is managed and advised by Fifth Street Management LLC. In June 2013, Fifth Street Finance Corp. announced that it has closed its portfolio company acquisition of Healthcare Finance Group, LLC (HFG).
Investments
The Company tailors the terms of its debt investments to the facts and circumstances of the transaction and prospective portfolio company. As of September 30, 2011, it directly originated a majority of its debt investments. It is focusing its origination efforts on first lien, second lien and subordinated loans. Its first lien loans have terms of four to six years, provide for a variable or fixed interest rate, contain prepayment penalties and are secured by a first priority security interest in all existing and future assets of the borrower. Its first lien loans may take many forms, including revolving lines of credit, term loans and acquisition lines of credit. Its second lien loans have terms of four to six years, provide for a fixed interest rate, contain prepayment penalties and are secured by a second priority security interest in all existing and future assets of the borrower. Its second lien loans often include payment-in-kind (PIK), interest, which represents contractual interest accrued and added to the principal that generally becomes due at maturity. Its unsecured inve! stments have terms of five to six years and provide for a fixed interest rate. It may make unsecured investments on a stand-alone basis, or in connection with a senior secured loan, a junior secured loan or a one-stop financing. Its unsecured investments may include payment-in-kind (PIK), interest, which represents contractual interest accrued and added to the principal that becomes due at maturity, and an equity component, such as warrants to purchase common stock in the portfolio company.
In addition, the Company from time to time non-control, equity co-investments in connection with private equity sponsors. It structures equity investments, such as direct equity co-investments, to provide the Company with minority rights provisions and event-driven put rights. The Company make investments in the private equity funds of certain of its equity sponsors. It makes these investments where it has a long term relationship and is comfortable with the sponsor�� business model and investment strategy. As of September 30, 2011, it had investments in six private equity funds, which represented less than 1% of the fair value of its assets as of such date.
Portfolio Management
As a business development company, the Company offers managerial assistance to its portfolio companies and to provide it if requested. It monitors the financial trends of each portfolio company to assess the appropriate course of action for each company and to evaluate overall portfolio quality. It has several methods of evaluating and monitoring the performance of its investments, which includes review of monthly and quarterly financial statements and financial projections for portfolio companies; periodic and regular contact with portfolio company management; attendance at board meetings; periodic formal update interviews with portfolio company management, and assessment of business development, including product development, profitability and the portfolio company�� overall adherence to its busine! ss plan.
In addition to various risk management and monitoring tools, the Company uses an investment rating system to characterize and monitor the credit profile and expected level of returns on each investment in itd portfolio. It uses a five-level numeric rating scale. In the event that it determines that an investment is underperforming, or circumstances suggest that the risk associated with a particular investment has significantly increased, it monitors the effected portfolio company.
Valuation of Portfolio Investments
As a business development company, the Company invests in illiquid securities, including debt and equity investments of small and mid-sized companies. The Company perform valuations of its debt and equity investments on an individual basis, using market, income, and bond yield approaches as appropriate. Under the market approach, it estimates the enterprise value of the portfolio companies, in which it invests. To estimate the enterprise value of a portfolio company, it analyze various factors, including the portfolio company�� historical and projected financial results. It requires portfolio companies to provide annual audited and quarterly and monthly unaudited financial statements, as well as annual projections for the upcoming fiscal year.
Under the income approach, the Company prepares and analyze discounted cash flow models based on projections of the future free cash flows of the business. Under the bond yield approach, it uses bond yield models to determine the present value of the future cash flow streams of its debt investments. It reviews various sources of transactional data, including private mergers and acquisitions involving debt investments with similar characteristics, and assess the information in the valuation process.
Advisors' Opinion:- [By Matthew Frankel]
Fifth Street Finance Corp. (NASDAQ: FSC ) is a business development company (BDC) that mainly lends to and invests in small and medium-sized companies. Despite its diversity, stable monthly dividend payments, and excellent yield, shares are actually trading at very nice discount.
- [By Amanda Alix]
With higher interest rates in the air, some of these companies point out that they have taken steps to plan for just such an occurrence. Fifth Street Finance (NASDAQ: FSC ) , in its June newsletter, tells its investors that its portfolio stands to gain from an upswing in short-term rates, since the loans they make tend to be of the floating rate variety, and the company's borrowing costs are fixed.
Top 10 Railroad Stocks To Own For 2014: SK Telecom Corporation Ltd.(SKM)
SK Telecom Co., Ltd. provides wireless telecommunications services using code division multiple access (CDMA) and wide-band CDMA technologies. It offers cellular voice services, such as wireless voice transmission services; and wireless global roaming services. The company also provides wireless data transmission services, such as wireless Internet access services, which allow subscribers to access online digital contents and services, as well as to send and receive text and multimedia messages. In addition, it offers broadband Internet and fixed-line telephone services, such as video-on-demand and IP TV services; and local, domestic, and international long-distance fixed-line telephone services to residential and commercial subscribers. Further, the company provides wireless entertainment-related contents and services, wireless finance-related contents and m-commerce services, and wireless news and search services; and international calling services, such as direct-dial, pre and post paid card calling services, bundled services for corporate customers, voice services using Internet protocol, Web-to-phone services, and data services. Additionally, it offers satellite digital media broadcasting services; telematics services; and fixed-line and online community portal services. The company also operates 11th Street, an online shopping mall; and T Store, an online open marketplace for mobile applications. As of March 31, 2011, SK Telecom Co. had 26 million wireless subscribers. It has strategic alliances with Bridge Alliance; Orange SA; Telecom Italia Mobile S.p.A.; T-Mobile International AG & Co; and Teliasonera Mobile Networks AB. The company was formerly known as Korea Mobile Telecommunications Co., Ltd. and changed its name to SK Telecom Co., Ltd. in March 1997. SK Telecom Co., Ltd. was founded in 1984 and is based in Seoul, South Korea.
Advisors' Opinion:- [By Garrett Cook]
Telecommunications services shares gained around 0.25 percent in today’s trading. Top gainers in the sector included NQ Mobile (NYSE: NQ), Allot Communications (NASDAQ: ALLT), and SK Telecom Co (NYSE: SKM).
Top 10 Railroad Stocks To Own For 2014: Natus Medical Incorporated(BABY)
Natus Medical Incorporated provides neurodiagnostic and newborn care products worldwide. The company offers healthcare products used for the screening, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. Its product offerings include neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; newborn care products, such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, and incubators to control the newborn?s environment; and software systems for managing and tracking disorders and diseases. The company provides newborn hearing screening product lines consisting of the ALGO, ABaer, AuDX, and Echo-Screen newborn hearing screeners; and hearing screening supply products that are used with newborn hea ring screening devices. It also offers diagnostic hearing assessment product lines, which include the Navigator Pro system, the Scout sport portable diagnostic device, and the AuDX PRO; and diagnostic hearing supply products. In addition, the company provides monitoring systems, balance and mobility products, newborn brain injury diagnostic products, thermoregulation products, and jaundice management products. Further, it offers photometers, radiometers, patient warming lamps, neonatal heatshields, pediatric scales, blanket warming cabinets, exam lights, oxygen hoods, restraining boards, and newborn circumstraints; neonatal noise attenuators, phototherapy eye masks, and x-ray shields for reproductive organs; and newborn screening data management products. The company serves hospitals, clinics, laboratories, physicians, nurses, audiologists, and governmental agencies. Natus Medical Incorporated was founded in 1987 and is headquartered in San Carlos, California.
Advisors' Opinion:- [By Sean Williams]
We could always blame Europe for the shortfall; I mean everyone else is doing it, right? Just yesterday, niche diagnostic and device maker for infants and newborns Natus Medical (NASDAQ: BABY ) warned that its revenue would be short of the Street's estimates because of tepid European demand for its products. Even having products with little competition in a niche category (infants and newborns) wasn't enough to save Natus Medical; could that be the reason Intuitive is faltering?
- [By Sean Williams]
What: Shares of Natus Medical (NASDAQ: BABY ) , a neurodiagnostic and medical device company specializing in newborn and infant care, sank as much as 15% after the company announced disappointing preliminary revenue figures for the second quarter.
Top 10 Railroad Stocks To Own For 2014: ImmunoGen Inc.(IMGN)
ImmunoGen, Inc. engages in the research and development of targeted therapeutics for the treatment of cancer using cancer biology, monoclonal antibodies, and highly potent cell-killing agents. The company develops its products using its Targeted Antibody Payload (TAP) technology. Its product candidates include Trastuzumab emtansine (T-DM1), a Phase III clinical trial product for HER2+ breast cancer; lorvotuzumab mertansine (IMGN901), a Phase I clinical trial product, which targets CD56 found on small-cell lung cancer, Merkel cell carcinoma, multiple myeloma, ovarian cancers, carcinoid tumors, and other cancers of neuroendocrine origin; IMGN529, a pre-investigational new drug stage drug for CD37+ B-cell malignancies, such as non-Hodgkin's lymphoma; and IMGN853, a preclinical stage product for cancers that overexpress folate receptor 1, including ovarian cancer. The company?s earlier-stage compounds in development stage comprise SAR3419, a Phase I clinical trial product for CD19+ B-cell malignancies, including non-Hodgkin's lymphoma; SAR650984, a Phase I clinical trial product for CD38+ hematological malignancies; SAR566658, a phase one clinical trial product for DS6+ solid tumors; and BT-062, a Phase I product for multiple myeloma. It has collaboration agreements with Amgen, Inc.; Bayer Schering Pharma AG; Biogen Idec MA Inc.; Biotest AG; Genentech, Inc.; Novartis Institutes for BioMedical Research, Inc.; and sanofi-aventis U.S. LLC. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
Advisors' Opinion:- [By Sean Williams]
Now what: We're still in the top of the second inning of a nine-inning game here, but ADCs certainly appear to be the future of cancer therapy -- at least one path to treating it. Immunomedics still has a long road to climb as its two ADC peers are much further along in their development process. ImmunoGen (NASDAQ: IMGN ) , for instance, already has an FDA-approved drug for late-stage HER2-positive breast cancer known as Kadcyla that utilizes the company's proprietary targeted-antibody payload technology (the same concept as ADCs with a different name) in combination with Roche's�Herceptin. In trials, this combo extended median overall survival by 5.8 months over the placebo to 30.9 months. Something similar can be said for Seattle Genetics�and its ADC pipeline.
- [By Lee Jackson]
While very upbeat on the sector as a whole, UBS was very cautious on sell-rated Ironwood Pharmaceuticals, Inc (NASDAQ: IRWD) and ImmunoGen Inc. (NASDAQ: IMGN). Neutral-rated Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) and Seattle Genetics Inc. (NASDAQ: SGEN) were also viewed with a skeptical eye.
- [By John Udovich]
Cramer Talks Up Biotech and Cancer Biotech in Particular. For what his opinion might be worth, MSNBC�� Mad Money host Jim Cramer recently commented that the 25 best-performing small cap stocks this year are "almost entirely biotech." He went on to point out that Celldex Therapeutics has been "just incredible��and that other companies to watch include Celgene Corporation (NASDAQ: CELG), ImmunoGen, Inc (NASDAQ: IMGN) and Onyx Pharmaceuticals, Inc (NASDAQ: ONXX), which all have promising cancer products on the way. He also added that:�
- [By RichardCox]
While it is important to seek out well-established companies with a proven product line, it should be remembered that it is still possible to find long-term opportunities in companies that are still in the clinical stage. In these cases, risk can be reduced by identifying those companies with a diversified set of drug innovations. So, when smaller companies are limited in the types of diseases and treatments, there is generally less protection from investment risk. One example of a smaller company with strong product positioning is ImmunoGen (IMGN).
No comments:
Post a Comment